The Longitudinal Idiopathic Intracranial Hypertension Trial: Outcomes From Months 6-12

Improvements in MD continued from month 6 to month 12 of the IIHTT in all treatment groups, most marked in the placebo group tapered off study drug. Adding ACZ to the placebo group significantly improved papilledema grade, headache, and QoL measures.